3-哌啶基苯酚 | 27292-50-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-哌啶基苯酚
• 英文名称: 3-(piperidin-1-yl)phenol
• 英文别名: 3-piperidinophenol；N-(3-hydroxyphenyl)-piperidine；N-m-hydroxyphenylpiperidine；3-piperidin-1-ylphenol
• CAS: 27292-50-8
• 化学式: C₁₁H₁₅NO
• mdl: MFCD00053001
• 分子量: 177.246
• InChiKey: YNLRDTBLEOQPQL-UHFFFAOYSA-N

物化性质

• 熔点：
  123-124 °C
• 沸点：
  338.9±25.0 °C(Predicted)
• 密度：
  1.106±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Piperidinophenol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Piperidinophenol
CAS number: 27292-50-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H15NO
Molecular weight: 177.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-哌啶基苯酚 在 盐酸 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 3.0h， 以88%的产率得到2-nitroso-5-(piperidin-1-yl)phenol
  参考文献：
  名称：

  [EN] NERVE-SPECIFIC FLUOROPHORE FORMULATIONS FOR DIRECT AND SYSTEMIC ADMINISTRATION
  [FR] FORMULATIONS DE FLUOROPHORE SPÉCIFIQUE AUX NERFS POUR ADMINISTRATION DIRECTE ET SYSTÉMIQUE

  摘要：

  描述了用于直接或全身给药的神经特异性荧光素配方。这些配方可用于荧光引导手术（FGS），帮助在外科手术干预期间保护神经。

  公开号：

  WO2020033435A1
• 作为产物：
  描述：

  间氨基苯甲醚 在 氢溴酸 、 sodium carbonate 、 甲苯 作用下， 生成 3-哌啶基苯酚
  参考文献：
  名称：

  The Reaction of 1,5-Dibromopentane with o-Substituted Anilines. The Synthesis of 1-Arylpiperidines¹

  摘要：

  DOI：

  10.1021/ja01117a041

文献信息

• [EN] 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES<br/>[FR] DERIVES DE 2,3,6-TRISUBSTITUE 4-PYRIMIDONE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2004085408A1

  公开（公告）日：2004-10-07

  A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C1-C12 alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C1-C8 alkyl group, an optionally partially hydrogenated C6-C10 aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, a C1-C6 alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C2-C6 alkylene group.

  一种具有tau蛋白激酶1抑制活性的嘧啶酮衍生物，其由化学式（I）或其盐、溶剂合物或水合物表示；用于预防和/或治疗神经退行性疾病（例如阿尔茨海默病）；其中Q代表CH或氮原子；R代表C1-C12烷基基团；化学式（I）的环：代表哌嗪环或哌啶环；每个X独立地代表C1-C8烷基基团、可选择性部分氢化的C6-C10芳环、茚环或类似物；m代表1到3的整数；每个Y独立地代表卤素原子、羟基、氰基、C1-C6烷基基团或类似物；n代表0到8的整数；当X和Y或两个Y基团连接在同一碳原子上时，它们可以结合形成C2-C6烷基基团。
• Novel amino acid ester and reagent composition for detecting leucocytes or elastase in body liquid
  申请人：KYOTO DAIICHI KAGAKU CO., LTD.

  公开号：EP0661280A1

  公开（公告）日：1995-07-05

  An amino acid ester of the formula: (X-O-A-)n-Y in which X is derived from an aromatic or heterocyclic compound: X-OH or its derivative; A is a residue of a L-amino acid, n is an integer of at least 2, and Y is a N-substituent of an amino acid derived from a compound having the same or different two or more carbonyl or sulfonyl groups which is formed from a single or complex compound selected from the group consisting of noncyclic or cyclic hydrocarbons having 1 to 10 carbon atoms, saturated or unsaturated heterocyclic compounds, aromatic compounds, organosilicon compounds having 1 to 10 silicon atoms, monosaccharides and oligosaccharide comprising 2 to 10 monosaccharides, all of which may have a substituent and/or a hetero atom to form the complex, which ester is specifically hydrolyzed by leucocytes or elastase.

  公式为(X-O-A-)n-Y的氨基酸酯，其中X源自芳香族或杂环化合物：X-OH或其衍生物；A是L-氨基酸的残基，n是至少为2的整数，Y是源自具有相同或不同的两个或更多个羰基或磺酰基的化合物的氨基酸的N-取代基，该化合物由选择自非环烃或环烃的群组成的单一或复杂化合物形成，该群包括具有1至10个碳原子的饱和或不饱和杂环化合物、芳香族化合物、具有1至10个硅原子的有机硅化合物、由2至10个单糖组成的单糖和寡糖，所有这些化合物均可具有取代基和/或杂原子以形成复合物，该酯特异地被白细胞或弹性蛋白酶水解。
• [EN] INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE<br/>[FR] INHIBITEURS DE LA CYSTATHIONINE BÊTA SYNTHASE UTILISABLES EN VUE DE LA RÉDUCTION DE LA SURPRODUCTION NEUROTOXIQUE DE SULFURE D'HYDROGÈNE ENDOGÈNE
  申请人：FOND JEROME LEJEUNE

  公开号：WO2013068592A1

  公开（公告）日：2013-05-16

  The invention is directed to inhibitors of cystathionine beta synthase which, among other biochemical effects, allow reduction of the neurotoxic overproduction of endogenous hydrogen sulphide. These compounds and pharmaceutical compositions containing them are useful for the prevention and treatment of cognitive disorders such as cognitive disorders in Down syndrome. The invention also relates to methods for preventing or treating cognitive disorders including cognitive disorders in Down Syndrome.

  本发明涉及胱硫醚β合酶抑制剂，除其他生化作用外，还允许减少内源性硫化氢的神经毒性过度产生。这些化合物以及含有它们的药物组合物对于预防治疗认知障碍，如下氏综合症中的认知障碍等是有用的。本发明还涉及用于预防或治疗认知障碍的方法，包括下氏综合症中的认知障碍。
• Stereodivergent Synthesis of Enantioenriched 2,3-Disubstituted Dihydrobenzofurans via a One-Pot C–H Functionalization/Oxa-Michael Addition Cascade
  作者：Dong-Xing Zhu、Jian-Guo Liu、Ming-Hua Xu

  DOI：10.1021/jacs.1c03498

  日期：2021.6.16

  A one-pot rhodium-catalyzed C–H functionalization/organocatalyzed oxa-Michael addition cascade reaction has been developed. This methodology enables the stereodivergent synthesis of diverse 2,3-disubstituted dihydrobenzofurans with broad functional group compatibility in good yields with high levels of stereoselectivity under exceptionally mild conditions. The full complement of stereoisomers of chiral

  已经开发了一种一锅铑催化的 C-H 官能化/有机催化的氧杂-迈克尔加成级联反应。该方法能够在极其温和的条件下以良好的收率和高立体选择性合成具有广泛官能团兼容性的多种 2,3-二取代二氢苯并呋喃。通过两种手性催化剂的适当排列，可以随意获得手性 2,3-二取代二氢苯并呋喃和 3,4-二取代异色满的完整立体异构体。目前的工作提供了一个罕见的例子，即两种手性催化剂在一次操作中通过两步反应独立控制两个连续的立体中心。
• Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor
  作者：Christoph Liechti、Urs Séquin、Guido Bold、Pascal Furet、Thomas Meyer、Peter Traxler

  DOI：10.1016/j.ejmech.2003.09.010

  日期：2004.1

  pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGFR protein tyrosine kinase and a putative binding mode of 4-anilinoquinazoline suggest that a salicylic acid function could serve as the pharmacophore replacement of a pyrimidine ring. Superpositions by CAMM of salicylanilides with the potent EGFR tyrosine kinase inhibitor 4-[(3'-chlorophenyl)amino]-6,7-dimethoxyquinazoline

  ATP竞争性抑制剂与EGFR蛋白酪氨酸激酶活性位点相互作用的药效团模型和推定的4-苯胺基喹唑啉结合模式表明，水杨酸功能可以用作嘧啶环的药效团替代。CAMM将水杨酰苯胺与有效的EGFR酪氨酸激酶抑制剂4-[（3'-氯苯基）氨基] -6,7-二甲氧基喹唑啉叠加显示水杨酰苯胺应作为酪氨酸激酶抑制剂。合成了一系列水杨酰苯胺，并确定了它们对酪氨酸激酶的抑制活性。实际上，其中一些确实被证明是有效的选择性EGFR酪氨酸激酶抑制剂。最有效的是28、16、20、6和15，IC（50）在23-71 nM范围内。